due to risk of serious liver injury, fda restricts use of obeticholic acid (ocaliva) in primary b...
Published 3 months ago • 62 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
28:12
reducing attrition due to drug-induced liver injury (dili) early in drug discovery
-
3:06
is your liver at risk? how the elf score can detect advanced fibrosis
-
54:52
doim gr 10/17/24: evaluation of risk
-
0:46
second-linetreatment for hcc
-
1:39
phase i/ii trial of adct-602 in b-all
-
42:52
role of dmpk in drug discovery and development
-
34:06
mechanisms of drug induced liver injury (dili) and the dili network experience
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
0:49
overview of the cll2-big trial of ibrutinib and obinutuzumab
-
0:49
overview of the cll2-big trial
-
1:44
codelivery of nrf 2 sirna and cyclophosphamide inhibits leukemia progression
-
1:24
the choice of a double-lung transplant
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
1:20
adverse cardiac events in copd patients treated with inhaled bronchodilators
-
54:53
discussing fda clearance of lyme immunoblot
-
4:27
atrial fibrillation, eloquis & new heart valve replacement devices (with dr. vinod thourani)
-
1:37
acalabrutinib may be an alternative to ibrutinib for treatment of cll
-
2:05
colorado's first double-lung and liver transplant
-
1:51
lrrk2: a pivotal regulator of neutrophil migration to infection sites
-
4:11
phase 2 trial shows improvements in pulmonary exacerbations in cystic fibrosis patients
-
32:35
03 - dr. sperling - risk factor burden and risk assessment of cardiovascular disease
-
2:24
breakthrough discovery in the fight against liver disease